Related Experiment Video

Updated: Dec 11, 2025

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.8K

The Impact of Hepatitis on Clinical Outcomes for Pediatric Patients with Aplastic Anemia

Wei-Hao Wang1, Jia-Feng Wu2, Hsiu-Hao Chang2

  • 1Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Pediatrics, Changhua Christian Hospital, Changhua, Taiwan.

The Journal of Pediatrics
|August 18, 2020
PubMed

Insights

Hepatitis-associated aplastic anemia in children indicates a worse survival prognosis. Nationwide hepatitis B vaccination may decrease the incidence of this condition.

Area of Science:

  • Pediatric Hematology
  • Hepatology
  • Epidemiology

Background:

  • Aplastic anemia is a rare but serious bone marrow failure disorder.
  • Hepatitis-associated aplastic anemia (HAAA) is a subtype with a variable prognosis.
  • The long-term impact of nationwide hepatitis B vaccination on HAAA incidence is not well-established.

Purpose of the Study:

  • To evaluate the prognostic significance of hepatitis in pediatric aplastic anemia.
  • To determine the incidence of hepatitis B in HAAA patients after 30 years of vaccination.
  • To assess the association between hepatitis B virus infection and aplastic anemia.

Main Methods:

  • Retrospective analysis of 78 pediatric aplastic anemia patients, including 9 with HAAA.
  • Collection of clinical data, etiologies, hepatitis B serology, viral load, treatment response, and survival.
  • Univariate and multivariate Cox regression and Kaplan-Meier survival analysis.

Main Results:

  • HAAA was independently associated with significantly worse survival outcomes compared to non-HAAA.
  • No cases of aplastic anemia were directly linked to hepatitis B virus infection in the study cohort.
  • The study provides insights into HAAA prognosis and potential vaccination impact.

Conclusions:

  • HAAA portends a poorer prognosis in pediatric aplastic anemia patients.
  • Nationwide hepatitis B vaccination may reduce the incidence of HAAA in children.
  • Further research is warranted to confirm these findings and explore underlying mechanisms.
Abstract

Keywords:
hepatitis B vaccinationhepatitis-associated aplastic anemiaimmunosuppressive therapy

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

358
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

16.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
104
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
129
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
110
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
147
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
106